UTHR Earnings Date: Nov 4, 2026 (Estimated) — United Therapeutics Corporation
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is UTHR's next earnings date?
United Therapeutics Corporation (UTHR) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $6.01 on revenue of $781.1M.
How did UTHR do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), United Therapeutics Corporation posted EPS of $7.27 versus the $6.86 estimate, a beat of 6.0%. Revenue was $783.3M against a $804.6M estimate. The stock's 1-day post-earnings move was +0.1%.
How much does UTHR stock move after earnings?
UTHR beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.4% (up or down) in the day after earnings.
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 6.86 | 7.27 | +5.98% | $783.3M | ✅ Beat | +0.06% | -0.61% | -5.14% |
| 2026-05-06 | Q1 2026 | 6.83 | 5.82 | -14.79% | $781.5M | ❌ Miss | +4.29% | +1.67% | -4.28% |
| 2026-02-25 | Q4 2025 | 6.77 | 7.70 | +13.74% | $790.2M | ✅ Beat | +13.03% | +5.33% | +14.40% |
| 2025-10-29 | Q3 2025 | 6.93 | 7.16 | +3.32% | $799.5M | ✅ Beat | +9.63% | +5.29% | +17.60% |
| 2025-07-30 | Q2 2025 | 6.87 | 6.41 | -6.70% | $798.6M | ❌ Miss | -5.25% | +2.44% | +2.62% |
| 2025-04-30 | Q1 2025 | 6.53 | 6.63 | +1.53% | $794.4M | ✅ Beat | +0.77% | -1.91% | +6.52% |
| 2025-02-26 | Q4 2024 | 6.31 | 6.19 | -1.90% | $735.9M | ❌ Miss | -10.80% | -13.68% | -13.06% |
| 2024-07-31 | Q2 2024 | 6.40 | 5.85 | -8.59% | $714.9M | ❌ Miss | -7.18% | -4.62% | +6.61% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $783.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Tyvaso | 57.8% | $452.6M | -3.6% | $415.9M | $466.3M | $469.6M | $478.0M |
| Remodulin | 16.1% | $126.3M | -6.2% | $134.5M | $138.2M | $134.7M | $125.9M |
| Orenitram | 16.0% | $125.7M | +1.5% | $107.8M | $120.7M | $123.9M | $131.1M |
| Unituxin | 8.3% | $65.2M | +11.6% | $67.5M | $58.2M | $58.4M | $47.9M |
| Product and Service, Other | 0.9% | $6.8M | +23.6% | $5.5M | $5.0M | $5.5M | $6.9M |
| Adcirca | 0.9% | $6.7M | +3.1% | $4.7M | $6.0M | $6.5M | $9.7M |
By region
Q2 FY26 · $783.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 93.7% | $733.6M | -3.4% | $705.7M | $749.6M | $759.8M | $774.8M |
| Non-US | 6.3% | $49.7M | +28.1% | $30.2M | $44.8M | $38.8M | $24.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.